We propose several steps to address this: stratifying patients by immunological risk, focusing on low-risk recipients without predisposing factors such as FcγRIIIA F-carrier status, and increasing infection monitoring for genetically susceptible patients. The gene discussed is FCGR3A; the disease is infection.